Apatinib is the first generation of oral antiangiogenesis drug invented in China, which mainly targets at VEGFR-2 as well as the receptor tyrosine kinase (RTK) such as c-kit, RET, and c-src.12 It was found that VEGF-2 promoted endothelial proliferation by activating the mitogen-activated protein kinase (MAPK) signaling pathway during the process of angiogenesis.13 And by blocking VEGFR-2, apatinib can suppress endothelial proliferation and finally lead to antiangiogenesis, which was confirmed to exerted an antitumor effect on various cancers.14 The gene discussed is RET; the disease is cancer.